Skip to main content

Table 5 Known group validity testing: effect sizes of the differences between the prostate and the testicular cancer samples

From: International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer

PCa versus TCa survivors
SF36: Physical Functioning 0.82
SF36: Role-Physical 0.73
SF36: Bodily Pain 0.69
SF36: General Health 0.51
SF36: Vitality 0.10
SF36: Social Functioning 0.23
SF36: Role-Emotional 0.48
SF36: Mental Health 0.25
QLQ-C30: Global health status/QoL 0.49
QLQ-C30: Physical Function 0.67
QLQ-C30: Role Function 0.44
QLQ-C30: Emotional Function 0.01
QLQ-C30: Cognitive Function 0.40
QLQ-C30: Social Function 0.33
QLQ-C30: Fatigue 0.06
QLQ-C30: Nausea / vomiting −0.16
QLQ-C30: Pain 0.30
QLQ-C30: Dyspnoea 0.29
QLQ-C30: Insomnia 0.18
QLQ-C30: Appetite loss 0.01
QLQ-C30: Constipation 0.31
QLQ-C30: Diarrhoea 0.05
QLQ-C30: Financial problems −0.02
IOC: Appearance concerns −0.03
IOC: Body change concerns 0.38
IOC: Life interferences 0.45
IOC: Worry −0.01
IOC: Negative Impact Scale 0.21
  1. Effect sizes are displayed in bold in those cases where the known groups differed significantly (p ≤ .05). PCa prostate cancer, TCa testicular cancer. A positive effect size reflects better HRQoL in TCa survivors